J Clin Oncol 32 (21): 2255-69, 2014.[PUBMED Abstract] Pan H, Gray R, Braybrooke J, et al.: 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
N Engl J Med 377 (19): 1836-1846, 2017.[PUBMED Abstract] Colleoni M, Gelber S, Goldhirsch A, et al.: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
J Clin Oncol 24 (9): 1332-41, 2006.[PUBMED Abstract] Fisher B, Dignam J, Bryant J, et al.: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.